Medtronic (1MDT) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1MDT Analyst Ratings

Moderate Buy

13 Buy

6 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Medtronic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1MDT Stock 12 Month Forecast

Average Price Target

€82.66

▲(12.71% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is €82.66 with a high forecast of €102.11 and a low forecast of €69.22. The average price target represents a 12.71% change from the last price of €73.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"62":"€62","103":"€103","72.25":"€72.3","82.5":"€82.5","92.75":"€92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":102.10500706,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€102.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.66128188705883,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€82.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.2237336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€69.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[62,72.25,82.5,92.75,103],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.46,75.66346208153846,77.86692416307692,80.07038624461538,82.27384832615384,84.4773104076923,86.68077248923076,88.88423457076922,91.0876966523077,93.29115873384615,95.49462081538462,97.69808289692308,99.90154497846154,{"y":102.10500706,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.46,74.16779091438913,74.87558182877828,75.58337274316742,76.29116365755657,76.9989545719457,77.70674548633484,78.41453640072399,79.12232731511313,79.83011822950226,80.53790914389141,81.24570005828055,81.9534909726697,{"y":82.66128188705883,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73.46,73.13413335384615,72.8082667076923,72.48240006153846,72.15653341538462,71.83066676923076,71.50480012307692,71.17893347692308,70.85306683076924,70.52720018461538,70.20133353846154,69.8754668923077,69.54960024615384,{"y":69.2237336,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.525,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.307,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.971,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.923,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.472,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.501,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.603,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.369,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.66,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.714,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.472,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.46,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€102.11

Average Price Target€82.66

Lowest Price Target€69.22

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Larry Biegelsen

Wells Fargo

€88.26

Buy

20.34%

Upside

Reiterated

08/05/26

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Medtronic (MDT)

Patrick Wood

UBS

€73.55→€86.53

Buy

17.98%

Upside

Upgraded

07/28/26

Medtronic upgraded to Buy from Neutral at UBSMedtronic upgraded to Buy from Neutral at UBS

Joanne Wuensch

Citi

€95.18

Buy

29.78%

Upside

Reiterated

07/22/26

Citi Remains a Buy on Medtronic (MDT)

Matthew O'Brien

Piper Sandler

€73.55

Hold

0.29%

Upside

Reiterated

07/14/26

Piper Sandler Reaffirms Their Hold Rating on Medtronic (MDT)

Ryan Zimmerman

BTIG

€77.88→€78.74

Buy

7.37%

Upside

Assigned

07/13/26

Medtronic price target raised to $91 from $90 at BTIGMedtronic price target raised to $91 from $90 at BTIG

Travis Steed

Bank of America Securities

€82.2

Buy

12.09%

Upside

Reiterated

07/13/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)

Shagun Singh Chadha

RBC Capital

€102.11

Buy

39.22%

Upside

Reiterated

07/13/26

Medtronic (MDT) Gets a Buy from RBC Capital

Mike Kratky

Leerink Partners

―

Buy

―

Reiterated

07/10/26

Leerink sees CPT proposal as 'clear net positive' signal for MedtronicLeerink sees CPT proposal as 'clear net positive' signal for Medtronic

Josh Jennings

TD Cowen

€102.97→€86.53

Buy

17.98%

Upside

Reiterated

07/10/26

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (Other OTC: SEMHF) and Medtronic (NYSE: MDT)

Vijay Kumar

Evercore ISI

€91.72→€90.86

Buy

23.88%

Upside

Reiterated

07/06/26

Medtronic price target lowered to $105 from $106 at Evercore ISIMedtronic price target lowered to $105 from $106 at Evercore ISI

Michael Matson

Needham

€87.39

Buy

19.16%

Upside

Reiterated

06/17/26

Medtronic: Renal Denervation Momentum Supports Multi-Catalyst Growth Story; Buy Rating and $101 Price Target Reaffirmed

Robbie Marcus

J.P. Morgan

€74.42

Hold

1.47%

Upside

Reiterated

06/05/26

J.P. Morgan Reaffirms Their Hold Rating on Medtronic (MDT)

Richard Newitter

Truist Financial

€82.2→€74.42

Hold

1.47%

Upside

Assigned

06/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Viatris (NASDAQ: VTRS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)

David Rescott

Robert W. Baird

€80.47→€73.55

Hold

0.29%

Upside

Reiterated

06/04/26

Medtronic price target lowered to $85 from $93 at BairdMedtronic price target lowered to $85 from $93 at Baird

David Roman

Goldman Sachs

€72.68→€71.82

Hold

-2.07%

Downside

Reiterated

06/04/26

Medtronic: Balanced Risk-Reward Keeps Hold Rating as Analyst Slightly Lowers Price Target to $83

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Larry Biegelsen

Wells Fargo

€88.26

Buy

20.34%

Upside

Reiterated

08/05/26

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Medtronic (MDT)

Patrick Wood

UBS

€73.55→€86.53

Buy

17.98%

Upside

Upgraded

07/28/26

Medtronic upgraded to Buy from Neutral at UBSMedtronic upgraded to Buy from Neutral at UBS

Joanne Wuensch

Citi

€95.18

Buy

29.78%

Upside

Reiterated

07/22/26

Citi Remains a Buy on Medtronic (MDT)

Matthew O'Brien

Piper Sandler

€73.55

Hold

0.29%

Upside

Reiterated

07/14/26

Piper Sandler Reaffirms Their Hold Rating on Medtronic (MDT)

Ryan Zimmerman

BTIG

€77.88→€78.74

Buy

7.37%

Upside

Assigned

07/13/26

Medtronic price target raised to $91 from $90 at BTIGMedtronic price target raised to $91 from $90 at BTIG

Travis Steed

Bank of America Securities

€82.2

Buy

12.09%

Upside

Reiterated

07/13/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Quest Diagnostics (NYSE: DGX) and Gilead Sciences (NASDAQ: GILD)

Shagun Singh Chadha

RBC Capital

€102.11

Buy

39.22%

Upside

Reiterated

07/13/26

Medtronic (MDT) Gets a Buy from RBC Capital

Mike Kratky

Leerink Partners

―

Buy

―

Reiterated

07/10/26

Leerink sees CPT proposal as 'clear net positive' signal for MedtronicLeerink sees CPT proposal as 'clear net positive' signal for Medtronic

Josh Jennings

TD Cowen

€102.97→€86.53

Buy

17.98%

Upside

Reiterated

07/10/26

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (Other OTC: SEMHF) and Medtronic (NYSE: MDT)

Vijay Kumar

Evercore ISI

€91.72→€90.86

Buy

23.88%

Upside

Reiterated

07/06/26

Medtronic price target lowered to $105 from $106 at Evercore ISIMedtronic price target lowered to $105 from $106 at Evercore ISI

Michael Matson

Needham

€87.39

Buy

19.16%

Upside

Reiterated

06/17/26

Medtronic: Renal Denervation Momentum Supports Multi-Catalyst Growth Story; Buy Rating and $101 Price Target Reaffirmed

Robbie Marcus

J.P. Morgan

€74.42

Hold

1.47%

Upside

Reiterated

06/05/26

J.P. Morgan Reaffirms Their Hold Rating on Medtronic (MDT)

Richard Newitter

Truist Financial

€82.2→€74.42

Hold

1.47%

Upside

Assigned

06/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Viatris (NASDAQ: VTRS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)

David Rescott

Robert W. Baird

€80.47→€73.55

Hold

0.29%

Upside

Reiterated

06/04/26

Medtronic price target lowered to $85 from $93 at BairdMedtronic price target lowered to $85 from $93 at Baird

David Roman

Goldman Sachs

€72.68→€71.82

Hold

-2.07%

Downside

Reiterated

06/04/26

Medtronic: Balanced Risk-Reward Keeps Hold Rating as Analyst Slightly Lowers Price Target to $83

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

3 Months

Anthony PetroneMizuho Securities

Success Rate

18/25 ratings generated profit

Average Return

+3.50%

Copying Anthony Petrone's trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +3.50% per trade.

1 Year

Vijay KumarEvercore ISI

Success Rate

13/20 ratings generated profit

Average Return

+3.38%

Copying Vijay Kumar's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +3.38% per trade.

2 Years

Vijay KumarEvercore ISI

Success Rate

16/20 ratings generated profit

Average Return

+7.95%

Copying Vijay Kumar's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +7.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1MDT Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1MDT has received 29 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 1MDT average Analyst price target in the past 3 months is 82.66.

Each month's total comprises the sum of three months' worth of ratings.

1MDT Financial Forecast

1MDT Earnings Forecast

Next quarter’s earnings estimate for 1MDT is €1.20 with a range of €1.18 to €1.22. The previous quarter’s EPS was €1.34. 1MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.49% of the time in the same period. In the last calendar year 1MDT has Performed in-line its overall industry.

1MDT Sales Forecast

Next quarter’s sales forecast for 1MDT is €8.26B with a range of €8.18B to €8.30B. The previous quarter’s sales results were €8.48B. 1MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.32% of the time in the same period. In the last calendar year 1MDT has Performed in-line its overall industry.

1MDT Stock Forecast FAQ

What is IT:1MDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Medtronic’s 12-month average price target is 82.66.

What is IT:1MDT’s upside potential, based on the analysts’ average price target?

Medtronic has 12.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Medtronic a Buy, Sell or Hold?

Medtronic has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.

What is Medtronic’s share price target?

The average share price target for Medtronic is 82.66. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €102.11 ,and the lowest forecast is €69.22. The average share price target represents 12.71% Increase from the current price of €73.34.

What do analysts say about Medtronic?

Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Medtronic?

To buy shares of IT:1MDT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Medtronic (1MDT) Stock Forecast & Price Target

1MDT Analyst Ratings

1MDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medtronic

1MDT Analyst Recommendation Trends

1MDT Financial Forecast

1MDT Earnings Forecast

1MDT Sales Forecast

1MDT Stock Forecast FAQ

Detailed List of Analyst Forecasts